Investment
Features
FeesSafety
Academy
More
Pluang+

Compare VanEck JP Morgan EM Local Currency Bond ETF (EMLC) vs Viatris Inc (VTRS) Price & Performance

VanEck JP Morgan EM Local Currency Bond ETFTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

VanEck JP Morgan EM Local Currency Bond ETF vs Viatris Inc — how do they compare? VanEck JP Morgan EM Local Currency Bond ETF trades at $24.84 (market cap $4.93B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 4.1× VanEck JP Morgan EM Local Currency Bond ETF's market cap, and Viatris Inc pays a 2.75% dividend while VanEck JP Morgan EM Local Currency Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck JP Morgan EM Local Currency Bond ETF for 38 Days and Viatris Inc for 57 Days on average.

EMLCVTRS
Market Cap
$4.93B$20.03B
Volume
2,843,86014,109,977
Sector
Fixed IncomeHealth
52-Week High
$26.59$18.27
52-Week Low
$24.53$9.74
Typical Hold Time
38 Days57 Days
Enterprise Value
—$32.15B
Dividend Yield
—2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

VanEck JP Morgan EM Local Currency Bond ETF

EMLC trades at $24.78, showing minimal daily movement with a 0.04% gain. The ETF recently hit a 52-week low, reflecting bearish technical signals from moving averages and ADX indicators. Recent news highlights challenges from dollar strength and Fed policy impacts on emerging market bonds. The fund maintains dividend distributions with recent payouts of $0.14 and $0.13 scheduled for October 2026.

Outlook remains cautious as technical indicators signal bearish momentum amid dollar strength. Investment opportunity exists for long-term investors seeking emerging market bond exposure with dividend income, though risks include currency volatility and rising U.S. interest rates pressuring local currency debt performance.

Viatris Inc

Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.

The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

EMLC
0% Buy100% Sell
Avg holding period · 38 Days
VTRS
100% Buy0% Sell
Avg holding period · 57 Days

Top news

Latest headlines on both assets

About VanEck JP Morgan EM Local Currency Bond ETF

EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.

Read more on EMLC →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →